Contact

Contact person:

CONTACT PERSON: Jostein Dahle
TITLE: Chief Scientific Officer (CSO)
PHONE: + 47 98 45 88 50
E-MAIL: jdahle@nordicnanovector.com
WEB SITE: http://www.nordicnanovector.com/

About

Founded in: 2009

Number of employees: 29

CEO: Luigi Costa

COMPANY DESCRIPTION:

Nordic Nanovector is a biotech company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology. The Company’s lead clinical-stage product opportunity is Betalutin®, the first in a new class of Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and complement current options for the treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing market worth over $12 billion by 2018. Betalutin® comprises a tumour-seeking anti-CD37 antibody, lilotomab (previously referred to as HH1), conjugated to a low intensity radionuclide (lutetium-177). The preliminary data has shown promising efficacy and safety profile in an ongoing Phase 1/2 study in a difficult-to-treat NHL patient population. The Company is aiming at developing Betalutin® for the treatment of major types of NHL with first regulatory submission anticipated in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation
of Betalutin® in core markets, while exploring potential distribution agreements in selected geographies. The Company is committed to developing its ARC pipeline to treat multiple selected cancer indications. Nordic Nanovector was established in 2009, leveraging expertise in targeted cancer therapy from the Norwegian Radium Hospital, and has its main office and laboratories in Oslo, Norway.

Role of the company in the incubator
Conduct preclinical studies of new product candidates.